Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy and SBRT for advanced cholangiocarcinoma
ChiCTR2400088480Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in cholangiocarcinoma (CCA) and biliary cancer, sponsored by Union Hospital. Primary endpoint: overall response rate. Started Aug 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
cholangiocarcinoma (CCA)biliary cancer
Beyond the preview
Go deeper on ChiCTR2400088480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088480.